Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/23/2026

1. GOOGL
2. TSLA
3. TXN
4. NOW
5. AMD
6. GOOG
7. INTC
8. CSX
9. KNX
10. IBM

Go back to Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)
(NASDAQ: AXSM) Delayed: 241.53 +1.91 (0.80%)
Previous Close $239.62    52 Week High $15.74 
Open $239.00    52 Week Low $5.37 
Day High $244.60    P/E N/A 
Day Low $237.00    EPS $0.00 
Volume 500,357